Business
OS Therapies to Participate in Upcoming Investor Conferences in September 2025
New York, New York--(Newsfile Corp. - September 3, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced that it will participate in the upcoming investor conferences:Cantor Global Healthcare Conference 2025 being held September 3-5, 2025 in New York City. Management will be available for meetings with institutional investors and brokersH.C. Wainwright 27th Annual
About this update from Os Therapies Incorporated
[{"type":"text","content":"New York, New York--(Newsfile Corp. - September 3, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced that it will participate in the upcoming investor conferences:","length":321,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Cantor Global Healthcare Conference 2025 being held September 3-5, 2025 in New York City. Management will be available for meetings with institutional investors and brokers","length":172,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"H.C. Wainwright 27th Annual Global Investment Conference being held September 8-10, 2025 in New York City. A pre-recorded presentation is available for conference participants and management will be available for meetings with institutional investors","length":250,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Lake Street Capital Markets 9th Annual Best Ideas Growth (BIG9) Conference being held on September 11, 2025 in New York City. Management will be available for meetings with institutional investors","length":196,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":618,"olType":false},{"type":"text","content":"About OS TherapiesOS Therapies is a clinical stage oncology company focused on the identification, development, and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. OST-HER2, the Company's lead asset, is an immunotherapy leveraging the immune-stimulatory effects of Listeria bacteria to initiate a strong immune response targeting the HER2 protein. OST-HER2 has received Rare Pediatric Disease Designation (RPDD) from the U.S. Food & Drug Administration and Fast-Track and Orphan Drug designations from the U.S. FDA and European Medicines Agency. The Company reported positive data in its Phase 2b clinical trial of OST-HER2 in recurrent, fully resected, lung metastatic osteosarcoma, demonstrating statistically significant benefit in the 12-month event free survival (EFS) primary endpoint of the study. The Company anticipates submitting a Biologics Licensing Application (BLA) to the U.S. FDA for OST-HER2 in osteosarcoma in 2025 and, if approved, would become eligible to receive a Priority Review Voucher t...